Biology of TNFα and IL-10, and their imbalance in heart failure
- 19 August 2008
- journal article
- review article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 14 (2) , 113-123
Abstract
Our understanding of the multiple in vivo functions of the proinflammatory cytokine, tumor necrosis factor (TNFα), is advancing at a rapid pace. In addition to its antitumor effects, overproduction of TNFα provokes tissue injury and organ failure. TNFα has also been shown to be cardiodepressent and responsible for various cardiovascular complications. It appears that still much needs to be learned for a full comprehension of the role of TNFα in heart biology. Another cytokine, interleukin-10 (IL-10), has been shown to have anti-inflammatory properties. It is suggested to counterbalance many adverse effects of TNFα. IL-10 suppresses the production of TNFα and many other proinflammatory cytokines. TNFα-induced oxidative stress is also known to be mitigated by IL-10. Moreover, improvement in cardiac function after treatment with various drugs is also shown to be associated with an increase in IL-10 content. Based on the data reviewed in here, it is suggested that an optimal balance between IL-10 and TNFα may be a new therapeutic strategy for a healthier heart.Keywords
This publication has 144 references indexed in Scilit:
- p38 and ERK1/2 MAPKs mediate the interplay of TNF-α and IL-10 in regulating oxidative stress and cardiac myocyte apoptosisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2007
- Oxidative Damage Precedes Nitrative Damage in Adriamycin-Induced Cardiac Mitochondrial InjuryToxicologic Pathology, 2004
- Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in miceNature Medicine, 2002
- Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathyThe Lancet, 1998
- The expanding universe of T-cell subsets: Th1, Th2 and moreImmunology Today, 1996
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.Journal of Experimental Medicine, 1993
- Cell killing and induction of manganous superoxide dismutase by tumor necrosis factor-(α is mediated by lipoxygenase metabolites of arachidonic acidBiochemical and Biophysical Research Communications, 1992
- Biological properties of interleukin 10Immunology Today, 1992
- Tumor necrosis factor Characterization at the molecular, cellular and in vivo levelFEBS Letters, 1991
- A Prospective, Randomized, Controlled Trial of Prednisone for Dilated CardiomyopathyNew England Journal of Medicine, 1989